Flazin as a Promising Nrf2 Pathway Activator

被引:19
|
作者
Fuda, Hirotoshi [1 ]
Miyanaga, Satoshi [1 ]
Furukawa, Takayuki [1 ]
Umetsu, Satomi [1 ]
Joko, Sae [1 ]
Roan, Yuning [1 ]
Suzuki, Hirotaka [1 ]
Hui, Shu-Ping [1 ]
Watanabe, Mitsugu [2 ]
Chiba, Hitoshi [3 ]
机构
[1] Hokkaido Univ, Fac Hlth Sci, Sapporo, Hokkaido 0600812, Japan
[2] Watanabe Oyster Lab Co Ltd, 490-3 Shimoongata Cho, Hachioji, Tokyo 1900154, Japan
[3] Sapporo Univ Hlth Sci, Dept Nutr, Higashi Ku, Nakanuma Nishi 4-2-1-15, Sapporo, Hokkaido 0070894, Japan
关键词
Keap1; Nrf2; hepatocyte; phase II enzyme; flazin; ORAC; MAILLARD REACTION-PRODUCTS; CULTURED HUMAN HEPATOCYTES; OYSTER CRASSOSTREA-GIGAS; OXIDATIVE STRESS; PHENOLIC ANTIOXIDANT; SOY-SAUCE; CELLS; CARCINOGENESIS; INDUCERS; METHYL;
D O I
10.1021/acs.jafc.9b04600
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
Flazin is a beta-carboline-derived alkaloid found in Japanese fermented foods. Here, the potential of flazin as an antioxidant food was studied with particular reference to its effect on the Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid 2-related factor 2 (Nrf2) system in human hepatocytes (C3A). Flazin and flazin analogues including the decarboxylated derivative perlolyrine were chemically synthesized and compared with each other and with chlorogenic acid and curcumin. Among these compounds, flazin showed the lowest cytotoxicity (IC50 < 500 mu M) and the highest capacity to activate the Keap1-Nrf2 system. It provided the largest (>3-fold of the control) cytoprotection ability against a pro-oxidant, although its radical absorbance capacity was relatively low. Flazin increased the expressions of Nrf2-dependent phase II enzyme genes and their products (NQO1, GSTP, and GSH proteins). The strong cytoprotection ability of flazin associated with low log P (0-3) is shared by sulforaphane and 3,5-dihydroxy-4-methoxybenzyl alcohol, suggesting the potential value of flazin and flazin-rich foods for the prevention of oxidation-related health disorders.
引用
收藏
页码:12844 / 12853
页数:10
相关论文
共 50 条
  • [31] Nrf2 pathway in patients with Parkinson's disease
    Schirinzi, T.
    Petrillo, S.
    Di Lazzaro, G.
    Mercuri, N.
    Bertini, E.
    Piemonte, F.
    Pisani, A.
    MOVEMENT DISORDERS, 2019, 34
  • [32] Repression of the Antioxidant NRF2 Pathway in Premature Aging
    Kubben, Nard
    Zhang, Weiqi
    Wang, Lixia
    Voss, Ty C.
    Yang, Jiping
    Qu, Jing
    Liu, Guang-Hui
    Misteli, Tom
    CELL, 2016, 165 (06) : 1361 - 1374
  • [33] The Study of Nrf2 Signaling Pathway in Ovarian Cancer
    Wu, Xiaotong
    Han, Li Ying
    Zhang, Xiao Xiao
    Wang, Ling
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2018, 28 (04): : 329 - 336
  • [34] Effects of atmospheric pollutants on the Nrf2 survival pathway
    Valentina Rubio
    Mahara Valverde
    Emilio Rojas
    Environmental Science and Pollution Research, 2010, 17 : 369 - 382
  • [35] VALIDATION OF NRF2 PATHWAY DYSREGULATION IN UROTHELIAL CARCINOMA
    Birch, Brian
    Lwaleed, Bashir
    Cooper, Alan
    Harper, Phil
    Giatsidou, Iliana
    JOURNAL OF UROLOGY, 2017, 197 (04): : E640 - E641
  • [36] Pyrrolidine dithiocarbamate activates the Nrf2 pathway in astrocytes
    Liddell, Jeffrey R.
    Lehtonen, Sarka
    Duncan, Clare
    Keksa-Goldsteine, Velta
    Levonen, Anna-Liisa
    Goldsteins, Gundars
    Malm, Tarja
    White, Anthony R.
    Koistinaho, Jari
    Kanninen, Katja M.
    JOURNAL OF NEUROINFLAMMATION, 2016, 13
  • [37] Targeting the Nrf2 pathway against cardiovascular disease
    Li, Jinqing
    Ichikawa, Tomonaga
    Janicki, Joseph S.
    Cui, Taixing
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (07) : 785 - 794
  • [38] Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer
    Telkoparan-Akillilar, Pelin
    Panieri, Emiliano
    Cevik, Dilek
    Suzen, Sibel
    Saso, Luciano
    MOLECULES, 2021, 26 (05):
  • [39] Keap1/Nrf2 Signaling Pathway
    Sykiotis, Gerasimos P.
    ANTIOXIDANTS, 2021, 10 (06)
  • [40] Influence of dietary flavonoids on the Nrf2/ARE signaling pathway
    Rohrig, R.
    Ruhl, S.
    Havermann, S.
    Gassmann, K.
    Schmitz, R.
    Bergermann, A.
    Chovolou, Y.
    Kahl, R.
    Fritsche, E.
    Waetjen, W.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2010, 381 : 68 - 68